In conclusion, our results show that universal FH screening in children is effective also for simultaneous identification of children with other rare dyslipidemia manifesting with hypercholesterolemia (such as LAL-D), as secondary screening conditions. The gene discussed is FH; the disease is metabolic syndrome.